Prognosis
Moderna Starts Study of Omicron-Specific Vaccine Booster
A healthcare worker prepares a dose of Moderna Covid-19 vaccine booster shot at a vaccination center in Keelung, Taiwan.
Photographer: I-Hwa Cheng/BloombergThis article is for subscribers only.
Moderna Inc. enrolled the first participant in a clinical trial of its omicron-specific vaccine booster, another step toward fighting the highly transmissible variant that’s spread around the world in a matter of weeks.
Moderna and rival Pfizer Inc. are each rushing to test omicron-specific vaccines in case they are needed as the variant continues to pummel the globe. Moderna’s statement on the new trial comes just one day after Pfizer said it had began a 1,400-person study of a messenger RNA shot targeted against omicron.